International Isotopes Inc. Reports 13.5% Increase in Product Sales; Net Loss Improves by 29% for First Half of 2025
International Isotopes Inc. $(INIS)$ has announced its financial results for the second quarter and the first six months ending June 30, 2025. The company reported a 15.3% increase in revenue from product sales for the second quarter of 2025, reaching $3.7 million, compared to the same period in 2024. For the first half of 2025, product sales rose by 13.5% to $6.9 million. The net loss for the second quarter of 2025 improved by 31.1% to $160,785 from a loss of $233,445 in the same period last year. Over the first six months of 2025, the net loss improved by 29.4% to $273,479 from $387,496 in the corresponding period of the previous year. The company's non-GAAP EBITDA for the second quarter increased to $1,199, a rise of $85,202, while the six-month figure improved by 157%, reaching $51,569. These financial improvements were largely driven by the robust performance in sales of Nuclear Medicine Standards products and Cobalt products.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. International Isotopes Inc. published the original content used to generate this news brief on August 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.